Lumito receives patent approval in India
Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company has been granted a patent in India relating to its technology for tissue analysis using upconverting nanoparticles. The patent has previously been granted in Europe and the United States and further strengthens Lumito’s international intellectual property protection. The granted patent protects the technology […]
Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit
Lumito AB (publ) (“Lumito” or the “Company”) today announces that two Swedish research customers have placed orders for the Company’s SCIZYS Erbium kit. The orders include the use of the Company’s Scan-as-a-Service offering and strengthen the Company’s position within the research segment. Both customers require the high sensitivity enabled by Lumito’s technology. The first order […]
Analyst Group initiates coverage of Lumito
Lumito AB (publ) (”Lumito” or the “Company”) today announces that Analyst Group has initiated equity research coverage of Lumito, commissioned by the Company. The coverage includes equity research with quarterly updates as well as analyst comments on financial reports and press releases. Analyst Group’s full equity research report on the Company is expected to be […]
Lumito’s technology enables quantification of low abundant cells
Lumito AB (publ) (“Lumito” or the “Company”) today announces new results from its collaboration with Truly Labs AB (“Truly Labs”), demonstrating that Lumito’s tissue analysis technology enables significantly improved detection of low abundant, “rare”, cells compared to conventional staining methods. The results were presented at the Pharma Outsourcing conference, organised by Life Science Sweden, on […]
Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe
Lumito AB (publ) (“Lumito” or the “Company”) is this week participating in one of Europe’s leading conferences for digital pathology, image analysis, and AI-driven technologies, the Digital Pathology & AI Congress: Europe in London. The conference gathers representatives from the pharmaceutical industry, CROs, hospital laboratories, academia, and technology companies to discuss developments within digital and […]
Lumito renews its quality certification, ISO 13485:2016
Lumito AB (publ) ("Lumito" or "the Company") today announces that the Company has had its quality certification renewed in accordance with the international standard ISO 13485:2016 – Medical devices – Quality management systems. The audit was carried out by the independent assessment body BSI Group and confirms Lumito’s clear focus on quality, safety, and regulatory […]
Lumito AB publishes interim report for the third quarter of 2025
Financial overviewThird quarter 2025, 1 July – 30 September• Net sales amounted to 0 (0) KSEK, capitalised development contributed with 0 (418) KSEK• The net loss amounted to -9 511 (-10 844) KSEK.• Basic and diluted earnings per share amounted to -0.04 (-0.05) SEK.• Cash flow during the third quarter amounted to -3 084 (-6 156) […]
Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report
Lumito AB (publ) (“Lumito” or the “Company”) will publish its report for the third quarter of 2025 on 27 November 2025. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:00 CET. During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction […]
Lumito granted SEK 250,000 business development grant from Region Skåne
Lumito AB (publ) (“Lumito” or “the Company”) announces today that the Company has received a business development grant of SEK 250,000 from Region Skåne. Together with the proceeds from the recently completed rights issue, the funding will primarily be used to accelerate the Company’s commercial development and further strengthen its position in the European market. […]
Conversion of paid subscribed units (BTUs) and first day of trading in warrants of series TO7
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]